04 / Policy · Policy
Vivisol’s home oxygen deal raises UK competition concerns
The UK competition regulator said it would open an in-depth investigation if the companies offered no remedies or if their proposals fell short.
Key points
- 01CMA publication of its Phase 1 decision summary on 19 Nov 2026
- 02Air Liquide Healthcare’s home oxygen services operation in south-west England
- 0326 Nov 2026 deadline for Vivisol and Air Liquide Healthcare to propose remedies
The Competition and Markets Authority (CMA), the UK competition regulator, published its Phase 1 decision summary (UK) on Vivisol’s proposed purchase of a business from Air Liquide Healthcare on 19 Nov 2026. The two companies have until 26 Nov 2026 to propose remedies.
Business covered. The CMA’s summary (UK) identifies the business as Air Liquide Healthcare’s home oxygen services operation in south-west England.
Competition finding. The CMA found that the acquisition could substantially lessen competition in the home oxygen services market (UK).
Remaining suppliers. The CMA found that only two other suppliers would remain in the UK home oxygen services market (UK) if the deal went ahead.
The CMA said it would refer the deal for an in-depth Phase 2 investigation (UK) if the companies offered no remedies by the deadline or if their proposals fell short. The decision summary gave no date for a possible referral.